(2023, April 20). Innovent Biologics announces overall survival results from phase two pemigatinib study in Chinese subjects with advanced cholangiocarcinoma. M2 Pharma.
Chicago Style (17th ed.) Citation"Innovent Biologics Announces Overall Survival Results from Phase Two Pemigatinib Study in Chinese Subjects with Advanced Cholangiocarcinoma." M2 Pharma 20 Apr. 2023.
MLA (9th ed.) Citation"Innovent Biologics Announces Overall Survival Results from Phase Two Pemigatinib Study in Chinese Subjects with Advanced Cholangiocarcinoma." M2 Pharma, 20 Apr. 2023.
Warning: These citations may not always be 100% accurate.